GlassScriptPhysician profile
James D Polk
NPI 1083601348
$2,692.93
in general payments reported to CMS, 2019-2025
27 companies · $55.70 in 2025
The $55.70 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $375 · 2021: $718 · 2022: $335 · 2023: $332 · 2024: $567 · 2025: $55.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $458.92 | 2020-2024 | |
| Glaxosmithkline, LLC. | $309.27 | 2021-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.80 | 2021-2024 | |
| Novo Nordisk INC | $210.66 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $209.17 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.67 | 2019-2021 | |
| Abbott Laboratories | $154.79 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Lilly USA, LLC | $134.15 | 2020-2024 | Mounjaro |
| Zimmer Biomet Holdings, INC. | $116.83 | 2020 | |
| Sunovion Pharmaceuticals INC. | $88.15 | 2019-2021 | |
| Allergan, INC. | $80.59 | 2020 | |
| Merck Sharp & Dohme LLC | $71.55 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.17 | 2022-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $54.53 | 2021-2024 | Farxiga, Airsupra |
| Inspire Medical Systems, INC. | $49.71 | 2024 | Inspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $35.58 | 2022 | |
| Vanda Pharmaceuticals INC. | $35.19 | 2019 | |
| Amgen INC. | $33.30 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $27.95 | 2023-2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $26.57 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $21.16 | 2024 | Unithroid |
| Antares Pharma, INC. | $16.30 | 2024 | Xyosted |
| Medtronic, INC. | $16.14 | 2023 | Intellis Adaptivestim |
| Mylan Specialty L.P. | $15.73 | 2019 | |
| Eisai INC. | $15.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.18 | 2019 | |
| Genentech USA, INC. | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Polk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.